Page last updated: 2024-12-07
3-hydroxymethylantipyrine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-hydroxymethylantipyrine : A pyrazolone that is antipyrine in which one of the hydrogens of the 5-methyl group is substituted by a hydroxymethyl group. It is a metabolite of the analgesic drug, antipyrene. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 123963 |
| CHEBI ID | 145210 |
| MeSH ID | M0099725 |
Synonyms (19)
| Synonym |
|---|
| 3-hydroxymethylantipyrine |
| 5-(hydroxymethyl)-1-methyl-2-phenylpyrazol-3-one |
| 5-(hydroxymethyl)-1-methyl-2-phenyl-1,2-dihydro-3h-pyrazol-3-one |
| CHEBI:145210 |
| 1,2-dihydro-5-(hydroxymethyl)-1-methyl-2-phenyl-3h-pyrazol-3-one |
| 2-methyl-3-(hydroxymethyl)-1-phenyl-3-pyrazolin-5-one |
| 18125-49-0 |
| 5-(hydroxymethyl)-1-methyl-2-phenyl-1h-pyrazol-3(2h)-one |
| 3-hmap |
| 3h-pyrazol-3-one, 1,2-dihydro-5-(hydroxymethyl)-1-methyl-2-phenyl- |
| 3f5ys569eb , |
| unii-3f5ys569eb |
| DTXSID00171087 |
| 1-phenyl-3-hydroxymethyl-2-methyl-3-pyrazolin-5-one |
| 3-(hydroxymethyl)-2-methyl-1-phenyl-3-pyrazolin-5-one |
| hydroxymethylantipyrine |
| CS-0246829 |
| 5-(hydroxymethyl)-1-methyl-2-phenyl-2,3-dihydro-1h-pyrazol-3-one |
| EN300-344575 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13." | ( The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. Bach, D; Blevins, R; Edwards, DJ; Kerner, N; Rubenfire, M, 1986) | 0.27 |
| " The first three months of life were characterised by a steady decrease in the apparent volume of distribution (aVd) and half-life (t0." | ( Effect of age on the pharmacokinetics of antipyrine in calves. Janus, K; Suszycka, J, 1996) | 0.29 |
| " The plasma elimination half-life of antipyrine was significantly elevated by 23% at 11 weeks postinfection (p." | ( Effect of experimental fasciolosis on antipyrine metabolism and clearance in water buffaloes. Bayón, JE; Ferre, I; González-Gallego, J; Jiang, SX; Mao, XZ, 2000) | 0.31 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Unknown additional peaks were detected in urine after NORA dosing but not after HMA or OHA administration." | ( The pharmacokinetics of antipyrine and three of its metabolites in the rabbit: intravenous administration of pure metabolites. Abul-Hajj, Y; Awni, WM; St Peter, JV, 1991) | 0.28 |
| " Mefloquine (750 mg) had no significant effect on salivary kinetics of antipyrine or on the metabolic clearance of antipyrine to its three main metabolites, 3-hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine, when antipyrine was administered either 2 h or 2 weeks after dosing with mefloquine." | ( The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. Back, DJ; Breckenridge, AM; Howells, RE; Rivière, JH, 1985) | 0.47 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
| Role | Description |
|---|---|
| drug metabolite | null |
| human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| pyrazolone | A member of the class of pyrazoles in which one of the carbons of the pyrazole ring is substituted by an oxo group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (50)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 28 (56.00) | 18.7374 |
| 1990's | 17 (34.00) | 18.2507 |
| 2000's | 3 (6.00) | 29.6817 |
| 2010's | 1 (2.00) | 24.3611 |
| 2020's | 1 (2.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.52
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.52) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (3.77%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 51 (96.23%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||